Peringatan Keamanan

There is limited information regarding acute toxicity and overdosage of tagraxofusp.

Tagraxofusp

DB14731

biotech approved investigational

Deskripsi

Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in Escherichia coli.A253762, A253887, L43702 Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is a myeloid malignancy in the dendritic cell lineage.A253762 It was also approved by the European Commission on January 7, 2021.L43712

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The mean (SD) terminal half-life of tagraxofusp was 0.7 (0.3) hours in patients with BPDCN.[L43702]
Volume Distribusi Following administration of tagraxofusp 12 mcg/kg via 15-minute infusion in patients with BPDCN, the mean (SD) volume of distribution of tagraxofusp was 5.1 (1.9) L.[L43702]
Klirens (Clearance) Mean clearance (SD) clearance was 7.1 (7.2) L/hr in patients with BPDCN.[L43702]

Absorpsi

Following administration of tagraxofusp 12 mcg/kg via 15-minute infusion in patients with BPDCN, the mean (SD) area under the plasma drug concentration over time curve (AUC) was 231 (123) hr x mcg/L and maximum plasma concentration (Cmax) was 162 (58.1) mcg/L.L43702

Metabolisme

Tagraxofusp is expected to be degraded into peptides and its constituent amino acids through proteolysis, with no involvement of CYP or transporters.L43712

Rute Eliminasi

No information available.

Interaksi Obat

38 Data
Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tagraxofusp.
Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tagraxofusp.
Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Tagraxofusp.
Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tagraxofusp.
Lidocaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Lidocaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Ropivacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Bupivacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Cinchocaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Dyclonine.
Procaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Procaine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Prilocaine.
Proparacaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Proparacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Meloxicam.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Oxybuprocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Cocaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Mepivacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Levobupivacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Diphenhydramine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Benzocaine.
Chloroprocaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Chloroprocaine.
Phenol The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Phenol.
Tetrodotoxin The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Tetrodotoxin.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Benzyl alcohol.
Capsaicin The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Capsaicin.
Etidocaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Etidocaine.
Articaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Articaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Tetracaine.
Propoxycaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Propoxycaine.
Pramocaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Pramocaine.
Butamben The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Butamben.
Butacaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Butacaine.
Oxetacaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Oxetacaine.
Ethyl chloride The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Ethyl chloride.
Butanilicaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Butanilicaine.
Metabutethamine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Metabutethamine.
Quinisocaine The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Quinisocaine.
Ambroxol The risk or severity of methemoglobinemia can be increased when Tagraxofusp is combined with Ambroxol.
Etrasimod The risk or severity of immunosuppression can be increased when Tagraxofusp is combined with Etrasimod.

Target Protein

Interleukin-3 receptor subunit alpha IL3RA

Referensi & Sumber

Artikel (PubMed)
  • PMID: 31548341
    Jen EY, Gao X, Li L, Zhuang L, Simpson NE, Aryal B, Wang R, Przepiorka D, Shen YL, Leong R, Liu C, Sheth CM, Bowen S, Goldberg KB, Farrell AT, Blumenthal GM, Pazdur R: FDA Approval Summary: Tagraxofusp-erzs For Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. Clin Cancer Res. 2020 Feb 1;26(3):532-536. doi: 10.1158/1078-0432.CCR-19-2329. Epub 2019 Sep 23.
  • PMID: 30621282
    Alkharabsheh O, Frankel AE: Clinical Activity and Tolerability of SL-401 (Tagraxofusp): Recombinant Diphtheria Toxin and Interleukin-3 in Hematologic Malignancies. Biomedicines. 2019 Jan 5;7(1). pii: biomedicines7010006. doi: 10.3390/biomedicines7010006.
  • PMID: 31018069
    Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, Rizzieri DA, Wang ES, Duvic M, Sloan JM, Spence S, Shemesh S, Brooks CL, Balser J, Bergstein I, Lancet JE, Kantarjian HM, Konopleva M: Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019 Apr 25;380(17):1628-1637. doi: 10.1056/NEJMoa1815105.

Contoh Produk & Brand

Produk: 2 • International brands: 0
Produk
  • Elzonris
    Injection, solution • 1000 ug/1mL • Intravenous • US • Approved
  • Elzonris
    Injection, solution, concentrate • 1 mg/ml • Intravenous • EU • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul